Dimension Capital’s $800M third fund shows the intersection of science and compute is booming
The four-year-old firm’s latest fund is 60% larger than its second vehicle announced 18 months ago.
Chai Discovery
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development
The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley’s most influential VCs.
OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation
Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.